Vaxcyte, Inc. (MUN:5VA)
Germany · Delayed Price · Currency is EUR | Market Cap | 5.88B +65.0% |
| Revenue (ttm) | n/a |
| Net Income | -820.93M |
| EPS | -5.99 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 41.20 |
| Previous Close | 42.60 |
| Day's Range | 41.20 - 41.20 |
| 52-Week Range | 25.80 - 51.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Vaxcyte
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]
News
Vaxcyte doses first participant in VAX-A1 study
Vaxcyte (PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1, the company’s investigational prophylactic vaccine candidate for the prevention of...
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026
VAX-31's phase III program is fully enrolled, with pivotal data expected in Q4 2024. The vaccine targets 31 serotypes, aiming for broader coverage and robust immune responses compared to current standards. Regulatory and commercial preparations are advancing, with market launch targeted for late 2025.
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
The company said, “With the recent completion of OPUS-3 enrollment, our OPUS-1, OPUS-2 and OPUS-3 adult Phase 3 trials are now fully enrolled, and we remain on track to deliver…
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte Quarterly report: Q1 2026
Vaxcyte has published its Q1 2026 quarterly earnings report on May 6, 2026.
Vaxcyte Earnings release: Q1 2026
Vaxcyte released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Vaxcyte Proxy statement: Proxy filing
Vaxcyte filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Vaxcyte Proxy statement: Proxy filing
Vaxcyte filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Vaxcyte Transcript: 25th Annual Needham Virtual Healthcare Conference
Upcoming 12–15 months will see pivotal data from adult and infant VAX-31 studies, with a BLA filing targeted by end of next year and potential approval in 2028. Market growth is driven by expanded adult vaccination and global recommendations, while strong financials support continued development.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
Vaxcyte (PCVX) announced the completion of enrollment in the VAX-31 OPUS-1 Phase 3 pivotal, noninferiority trial with approximately 4,000 participants and the OPUS-2 Phase 3 trial evaluating VAX-31 co...
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capva...
Vaxcyte Slides: Corporate presentation
Vaxcyte has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
The company states: “Vaxcyte (PCVX) announced the publication of results from the positive VAX-31 adult Phase 1/2 clinical study in the journal The Lancet Infectious Diseases. The study evaluated the…
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data f...
Vaxcyte Transcript: Leerink Global Healthcare Conference 2026
The company is advancing its 31-valent pneumococcal vaccine, VAX-31, through pivotal phase III trials with results expected by mid-2025 and a BLA filing targeted by year-end 2025. A novel Group A Strep vaccine will enter clinical trials in 2024, addressing a major unmet need.
Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference
VAX-31, a 31-valent pneumococcal vaccine, is advancing through pivotal phase 3 trials with key data expected this year and next. Innovative conjugation technology enables broader serotype coverage and improved immune responses, while regulatory and market dynamics favor expanded adult vaccination. Group A Strep vaccine development and global market growth further strengthen the outlook.
Vaxcyte price target raised to $89 from $85 at BTIG
BTIG raised the firm’s price target on Vaxcyte (PCVX) to $89 from $85 and keeps a Buy rating on the shares after its Q4 results. The details have led to…
Vaxcyte price target lowered to $133 from $134 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Vaxcyte (PCVX) to $133 from $134 and keeps a Buy rating on the shares. The firm, which sees “no surprises”…
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Vaxcyte (PCVX) to $67 from $38 and keeps a Neutral rating on the shares. Since coverage initiation, shares have risen steadily due…
Vaxcyte price target raised to $75 from $50 at TD Cowen
TD Cowen analyst Tara Bancroft raised the firm’s price target on Vaxcyte (PCVX) to $75 from $50 and keeps a Buy rating on the shares. The firm said Vaxcyte enters…
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
“In 2025, we made meaningful progress across clinical development, regulatory engagement and commercial manufacturing readiness as we advanced our broad-spectrum pneumococcal conjugate vaccine franchi...